Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHuVIZwUUN3ME21Mlg3PjZizszN MVvTRW5ITVJ?
DOHH-2 M4fBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTlwM{W2PFkh|ryP NUX3TY5oW0GQR1XS
no-10 M1rqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXKTWM2OD17LkmwN|kh|ryP M3;mdHNCVkeHUh?=
LS-513 NFf1b4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXZRVFOUUN3ME2xNU4{PTR5IN88US=> NG\lNJZUSU6JRWK=
ALL-PO NX;KUmd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nYcWlEPTB;MUGuO|c{PCEQvF2= NWG5TGdpW0GQR1XS
8-MG-BA NYnheVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT0TWM2OD1zMz6xNVI{KM7:TR?= NGL3OFhUSU6JRWK=
RPMI-8402 NXjJOml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nXdmlEPTB;MUWuPFU{PyEQvF2= M4TU[nNCVkeHUh?=
EoL-1-cell NVHQToQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnwTlRKSzVyPUG4MlU6PDhizszN NYju[WVkW0GQR1XS
NALM-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF7LkCxOlch|ryP MVLTRW5ITVJ?
DEL MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmftTWM2OD1{MD6xOFcyKM7:TR?= MkPIV2FPT0WU
SR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G1bWlEPTB;MkOuOlcyPSEQvF2= NGDTXmhUSU6JRWK=
697 NHv2Z3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zn[GlEPTB;Mk[uOlE2PSEQvF2= MWHTRW5ITVJ?
COLO-829 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ4Lki0PFMh|ryP NV3nRpRmW0GQR1XS
EVSA-T M4rZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XzXWlEPTB;MkeuOVU3OSEQvF2= M1rsVHNCVkeHUh?=
ATN-1 M2\CdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zYSWlEPTB;M{GuNlMzQSEQvF2= MkTEV2FPT0WU
L-363 NX:zO21FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfFTWM2OD1|MT63OFYyKM7:TR?= MXHTRW5ITVJ?
LAMA-84 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXOTWM2OD1|Mj61NlEyKM7:TR?= Moj0V2FPT0WU
NOS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnLU|RKSzVyPUO0MlI6PTZizszN MmrZV2FPT0WU
BB30-HNC NIj3VFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK5[mVqUUN3ME2zOE4{OzB4IN88US=> MmLNV2FPT0WU
BC-1 NF72O4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnSZ41uUUN3ME2zO{46PzR4IN88US=> M1;3[XNCVkeHUh?=
IST-SL2 M{DsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITZcopKSzVyPUO4MlIzPCEQvF2= M3;oe3NCVkeHUh?=
D-392MG NI\HfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjrdmlKSzVyPUSwMlIzOTVizszN NWe5eJJJW0GQR1XS
no-11 M1XCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\ve2JnUUN3ME20NE42PTJzIN88US=> M3e1fXNCVkeHUh?=
LC4-1 NFjNdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\YfplOUUN3ME20NE45PzF4IN88US=> MYTTRW5ITVJ?
A388 M{nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHNXpRtUUN3ME20Nk42QDR6IN88US=> MlLiV2FPT0WU
NTERA-S-cl-D1 NYTq[W1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR{LkewO|Qh|ryP MUnTRW5ITVJ?
CESS M4naTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS5SHBKSzVyPUS0MlIzOzJizszN M{jY[3NCVkeHUh?=
RS4-11 NEjRcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PTZWlEPTB;NEmuNFk{QCEQvF2= M{D5XXNCVkeHUh?=
MS-1 NIj4VnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;XTWM2OD13MD65N|UyKM7:TR?= NI\rSGxUSU6JRWK=
CTV-1 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTVzLkC3OEDPxE1? MlrKV2FPT0WU
D-502MG NEnGdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVzLk[yO|Eh|ryP MYTTRW5ITVJ?
ML-2 M2LqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWyTWM2OD13Mj65NVk2KM7:TR?= NHHqbWdUSU6JRWK=
SK-NEP-1 NYL2RVI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTV|LkO5NlMh|ryP MnfuV2FPT0WU
LOXIMVI MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37uW2lEPTB;NUOuOVg5PCEQvF2= NEPyPIFUSU6JRWK=
DJM-1 MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\aTWM2OD13Nj6zN|kyKM7:TR?= M4fCO3NCVkeHUh?=
GI-1 NH;NVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTV4Lk[xOFkh|ryP NYnCXVVJW0GQR1XS
IST-MES1 NXnFWYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnnbHdFUUN3ME22NE42PDl|IN88US=> MYPTRW5ITVJ?
MV-4-11 NYWzdY9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTZyLk[1N|gh|ryP M1K5W3NCVkeHUh?=
OVCAR-4 NEjXSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjQXXNKSzVyPU[zMlU3PTdizszN NIeyWYFUSU6JRWK=
KE-37 NXLUR2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\TVGlEPTB;Nk[uNlY3QCEQvF2= NISzXnBUSU6JRWK=
D-542MG M3fMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2UWlKSzVyPU[4MlQyOzVizszN M1PZTXNCVkeHUh?=
MHH-PREB-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17Cc2lEPTB;N{KuPFQ1OSEQvF2= MV\TRW5ITVJ?
MRK-nu-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LDTmlEPTB;N{OuOFcxPSEQvF2= NEL6c5hUSU6JRWK=
D-247MG NWnoUFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3roTGlEPTB;N{OuOVQ1OiEQvF2= M2P1U3NCVkeHUh?=
OCI-AML2 NFjOVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX6fopCUUN3ME23Ok46OzZ7IN88US=> M1Gz[3NCVkeHUh?=
LP-1 M3f6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zmT2lEPTB;OEKuPFc{OSEQvF2= MVfTRW5ITVJ?
HCC1599 M1\CTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTh2LkK4N|ch|ryP M4mxfHNCVkeHUh?=
KARPAS-45 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nWWGlEPTB;OESuOlk6OiEQvF2= NXHsRo5EW0GQR1XS
BE-13 NH;HS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3FTWM2OD17OT6wOFc4KM7:TR?= NEHvXm1USU6JRWK=
GCIY NYD6fYFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3hTWM2OD17OT6wPVU1KM7:TR?= M3uzfHNCVkeHUh?=
BV-173 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WwXmlEPTB;MUCwMlMzPSEQvF2= MnLZV2FPT0WU
LB2518-MEL NFLCeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnVOGY5UUN3ME2xNFAvPzh7IN88US=> M1XHUXNCVkeHUh?=
KS-1 NHLsTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7TTWM2OD1zMEGuOlM6KM7:TR?= NUS0XpdtW0GQR1XS
MOLT-16 NYr1WoFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFyND65PFYh|ryP MX3TRW5ITVJ?
NCI-H1770 NWPkeXdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6zXWpKSzVyPUGwPE44QDRizszN Ml3ZV2FPT0WU
NCI-H82 M1TYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTxVm1UUUN3ME2xNVAvQTd4IN88US=> MkLCV2FPT0WU
NCCIT NWrNToFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M362bmlEPTB;MUGyMlUzQSEQvF2= MYHTRW5ITVJ?
KALS-1 NGrWZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\mcYVlUUN3ME2xNVUvQTRzIN88US=> MmnHV2FPT0WU
LB2241-RCC NEnZdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFzNj62O|kh|ryP NV\UWJhDW0GQR1XS
HH Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPOfXhKSzVyPUGxO{4{QTVizszN MWDTRW5ITVJ?
HD-MY-Z NIjSR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;jSllKSzVyPUGxPE41QDhizszN MkG3V2FPT0WU
EB-3 NX32XGc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvPeYdKSzVyPUGyN{4xQTRizszN MWHTRW5ITVJ?
BL-70 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF{Mz6xNlch|ryP NFjR[o1USU6JRWK=
K-562 NHO2blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Kx[GlEPTB;MUK2MlI1PSEQvF2= M{THXnNCVkeHUh?=
HT-144 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF|Mz6xOlQh|ryP MoCxV2FPT0WU
PF-382 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTQfoJ{UUN3ME2xN|QvOzZzIN88US=> MYHTRW5ITVJ?
RPMI-8226 NWDUZZV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj6RVNuUUN3ME2xN|UvODR3IN88US=> M3zCVnNCVkeHUh?=
NCI-H1355 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF|NT61PFch|ryP M3K4dXNCVkeHUh?=
LXF-289 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF|OT63PFEh|ryP NXTES3E{W0GQR1XS
NCI-H69 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M376c2lEPTB;MUSyMlk{OiEQvF2= MojPV2FPT0WU
SK-MEL-1 NEHOWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF2Nz6xN{DPxE1? MnLiV2FPT0WU
KARPAS-299 NY\BeIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzndJRnUUN3ME2xOFkvOTJizszN NIjqb4pUSU6JRWK=
GB-1 NEHiW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF2OT6zNlIh|ryP MoO1V2FPT0WU
CMK NWCweHB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\qd2lEPTB;MUS5MlUyPSEQvF2= M3vZWXNCVkeHUh?=
MPP-89 NHvSTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF3Nj6wN|Uh|ryP NVrz[FhPW0GQR1XS
KU812 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PvNWlEPTB;MU[xMlkxOiEQvF2= NVGwXXFRW0GQR1XS
REH NYLvfJRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPOSVJKSzVyPUG2Nk4yOjVizszN MnrBV2FPT0WU
NEC8 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TYRWlEPTB;MU[1MlAzPiEQvF2= NVvkXW5VW0GQR1XS
KP-N-YS Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Xl[2lEPTB;MU[4MlM6PSEQvF2= M37GR3NCVkeHUh?=
Ramos-2G6-4C10 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfZTWM2OD1zNkmuPVE2KM7:TR?= MmHjV2FPT0WU
Becker Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4noZmlEPTB;MUe0MlE5KM7:TR?= MXzTRW5ITVJ?
LB647-SCLC NIXqOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF5NT64OFUh|ryP MojyV2FPT0WU
LU-139 NH\RdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF5OD6wNVkh|ryP MoPSV2FPT0WU
QIMR-WIL M3zGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF5OT62OFYh|ryP MYTTRW5ITVJ?
NCI-H1395 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHexXpNKSzVyPUG3PU46QTZizszN NHTUT2ZUSU6JRWK=
NOMO-1 NXrFZ3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH0UZEzUUN3ME2xPFIvQDVizszN MnfaV2FPT0WU
GI-ME-N MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XKcWlEPTB;MUi3Mlk3QSEQvF2= MnPpV2FPT0WU
KMS-12-PE Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nWO2lEPTB;MUi5MlI4OyEQvF2= MmjGV2FPT0WU
Daudi NHToVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\KbWlDUUN3ME2xPVEvOTJ6IN88US=> MYLTRW5ITVJ?
LB996-RCC NWTEZW1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF7MT62PVkh|ryP NIfocnJUSU6JRWK=
NCI-H2107 NH:5NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vGfWlEPTB;MUmzMlc{QSEQvF2= M13hcXNCVkeHUh?=
SK-PN-DW NEDXV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF7ND63NVkh|ryP NXnRV2JDW0GQR1XS
MC-CAR MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TyZmlEPTB;MkCyMlI2OyEQvF2= NUPMZnpKW0GQR1XS
SNB75 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLGVmlKSzVyPUKyNU46PCEQvF2= NHTnbWNUSU6JRWK=
ES4 M1Hadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\qbo5KSzVyPUKyN{44QDNizszN NFzXWodUSU6JRWK=
KARPAS-422 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;QTWM2OD1{MkiuN|UzKM7:TR?= M3zWXXNCVkeHUh?=
NCI-H1648 NUnDcmN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TPZ2lEPTB;MkK5MlQ5QSEQvF2= NHj6UXRUSU6JRWK=
ES6 NFHOb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfRN|IzUUN3ME2yN|kvPDNizszN MoXHV2FPT0WU
KNS-81-FD MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG4NVNrUUN3ME2yOFEvOTl5IN88US=> M4fPfXNCVkeHUh?=
JAR MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ3Nj6yNlUh|ryP NHK1VHFUSU6JRWK=
NB1 NGPH[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\XU4R3UUN3ME2yOlAvPTF4IN88US=> Mn\aV2FPT0WU
D-336MG NH\KXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ4MD62PVgh|ryP MY\TRW5ITVJ?
BC-3 NFvBN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW0TWM2OD1{NkWuNVc5KM7:TR?= MX3TRW5ITVJ?
HCC2218 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LreWlEPTB;Mk[2MlQyPSEQvF2= NYm5N5pGW0GQR1XS
TE-9 NXH0RWxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzVTWM2OD1{Nk[uOlI4KM7:TR?= M4C5R3NCVkeHUh?=
LB1047-RCC NILlZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfmcYs4UUN3ME2yOlYvPzV|IN88US=> MnLjV2FPT0WU
CTB-1 M364Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\K[WxKSzVyPUK2PU46PzNizszN M4\JVXNCVkeHUh?=
NB7 NE\ke49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2flRKSzVyPUK3NUDPxE1? NF\3R|dUSU6JRWK=
ST486 NGPPcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKxTWM2OD1{N{euOFEzKM7:TR?= NX;peJVwW0GQR1XS
HCC1187 NH3KUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPhR5hCUUN3ME2yPFIvQDFzIN88US=> NED3SYtUSU6JRWK=
NCI-SNU-16 NXzRflZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETwV5pKSzVyPUK4OE4zPDhizszN M1TJbnNCVkeHUh?=
COR-L279 NULLSFZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ7MT61PFQh|ryP NGHveJVUSU6JRWK=
ES8 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ7ND6xPFIh|ryP Mm\VV2FPT0WU
U-698-M NVTibXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvwTWM2OD1{OUiuNlQ{KM7:TR?= MYDTRW5ITVJ?
HEL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DNTGlEPTB;M{C5MlE1QSEQvF2= MUHTRW5ITVJ?
KINGS-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNzMD62O|Qh|ryP MUfTRW5ITVJ?
KY821 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rJbWlEPTB;M{O2MlU6PSEQvF2= NIDMeI1USU6JRWK=
MZ1-PC M3rBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLzTpdWUUN3ME2zOFUvPjF6IN88US=> NXTn[YVYW0GQR1XS
LS-411N NWLkW49KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjp[HBjUUN3ME2zOVQvPjZizszN NUnWTVlVW0GQR1XS
SIG-M5 M4CyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLnTWM2OD1|NUmuO|gzKM7:TR?= MUfTRW5ITVJ?
HT M4rtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jabmlEPTB;M{[3MlcyOSEQvF2= M1zFeXNCVkeHUh?=
HC-1 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn1NpVKSzVyPUO2O{44QDdizszN MV;TRW5ITVJ?
NCI-H1694 NFPEXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN5Mj65N|Qh|ryP NXjLRVV{W0GQR1XS
BB65-RCC M1vSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTN5Nj6yOFUh|ryP MVrTRW5ITVJ?
HAL-01 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7qVVRKSzVyPUO3PU45OzhizszN NFHsXHFUSU6JRWK=
ARH-77 M1HxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF30ZpFKSzVyPUO5OE4xODhizszN NIHhXmpUSU6JRWK=
MZ7-mel M1znV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN7Nz6yN|Mh|ryP MmXJV2FPT0WU
SIMA NGDtN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLuTWM2OD12MEOuPVM{KM7:TR?= NVWyc4hNW0GQR1XS
DG-75 NX\aZ49zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRzNT62PVgh|ryP NETVUXZUSU6JRWK=
HUTU-80 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjvTWM2OD12MUmuNVg2KM7:TR?= M3;jZnNCVkeHUh?=
KNS-42 NWfrSGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DLWGlEPTB;NEK1MlgyPSEQvF2= M1TYWnNCVkeHUh?=
SH-4 M2rofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvjTYdKSzVyPUSyO{42PjVizszN MnWwV2FPT0WU
L-540 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7TVVFKSzVyPUSzNU4xOzFizszN MUXTRW5ITVJ?
NB10 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq5[IRKSzVyPUS0NU4zOzRizszN M3;md3NCVkeHUh?=
ES1 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR3Mj63OVMh|ryP MVnTRW5ITVJ?
KMOE-2 NFrjO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fMPWlEPTB;NEW2MlcyOSEQvF2= NXrlWHh1W0GQR1XS
MC116 M{HGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\GTWM2OD12NUiuNVE3KM7:TR?= NUPofHBUW0GQR1XS
RCC10RGB NH7UR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDuTWM2OD12NkCuNFA2KM7:TR?= NWXrcHVrW0GQR1XS
RL95-2 NYHCe4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fiPWlEPTB;NE[wMlI{PyEQvF2= M{LGSXNCVkeHUh?=
Raji MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTUTWM2OD12NkiuNVQ{KM7:TR?= M4G1XHNCVkeHUh?=
CAS-1 M4HnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTR5Mj6wO|Mh|ryP NFrjOmpUSU6JRWK=
Calu-6 NYC1UHJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLXcpd4UUN3ME20O|UvOjZ3IN88US=> MmHDV2FPT0WU
KG-1 M4GxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nWfGlEPTB;NEe4MlQ1KM7:TR?= M4TycnNCVkeHUh?=
LB771-HNC M{nZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISyeIJKSzVyPUS4Nk4zOzJizszN MUjTRW5ITVJ?
ACN NETFPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTHTWM2OD12OUOuOVk6KM7:TR?= M{XK[HNCVkeHUh?=
KM12 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLuTWM2OD12OU[uOVg6KM7:TR?= Mn\YV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
in solvent
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID